The problem is solved by compounds according to general formula (I) as shown in the figure above. Detailed in vitro characterisation of compounds is already done as well as first in vivo tests on Staphylococcus aureus.
Next planned steps are more substantial in vivo tests, especially with Vancomycin-resistent S. aureus strains.
Beneficially, the compounds according to the invention can be useful as an antibacterial substance in the treatment of bacterial infection. The present invention therefore provides a novel approach to the treatment of bacterial infection.
On behalf of the Universities of Bonn and Konstanz, PROvendis is offering access for commercial use in terms of a license as well as research collaboration to innovative companies.
A European and a US-patent application have been filed.